Geron stocks.

Dec 30, 2022 · See GERN Report. Geron Corporation ( GERN) is near the top in its industry group according to InvestorsObserver. GERN gets an overall rating of 80. That means it scores higher than 80 percent of stocks. Geron Corporation gets a 95 rank in the Biotechnology industry. Biotechnology is number 48 out of 148 industries. GERN has an Overall Score of 80. Asterias has ties to a stock promotion and faces a near-term need to raise significant capital. Asterias' pipeline was abandoned by Geron in 2011 after showing no signs of efficacy in its first ...A high-level overview of Geron Corporation (GERN) stock. Stay up to date on the latest stock price, chart, news, analysis, fundamentals, trading and investment tools.Previous Close $1.79. Volume 4.46M. Average Volume (3M) 5.74M. Market Cap. $936.83M. Enterprise Value $620.85M. Total Cash (Recent Filing) $371.91M. Total Debt (Recent Filing) $55.93M. Price to Earnings (P/E) -4.9.Geron — Stock in the biotechnology firm added roughly 1.7% following an upgrade to buy from Goldman Sachs earlier Tuesday. Analyst Corinne Jenkins noted optimism over recent U.S. Food and Drug ...

How much institutional selling is happening at Geron? Institutional investors have sold a total of 55,005,341 shares in the last 24 months. This volume of shares sold represents approximately $136.20M in transactions. This page (NASDAQ:GERN) was last updated on 11/21/2023 by MarketBeat.com Staff.In January 2023, the Company closed an underwritten public offering of common stock and pre-funded warrant, plus the full exercise of the underwriters’ option to purchase additional shares of ...Oct 3, 2023 · Given the large stake in the stock by institutions, Geron's stock price might be vulnerable to their trading decisions ; 51% of the business is held by the top 15 shareholders ; Insiders have been buying lately ; Every investor in Geron Corporation (NASDAQ:GERN) should be aware of the most powerful shareholder groups. We can see that ...

Geron's stock rises on positive Phase 3 trial results for its myelodysplastic syndrome drug, imetelstat, potentially improving treatment for certain...

Geron Corporation is a biopharmaceutical company with its headquarters located in Menlo Park, California. According to a press release dated December 22, ... 2010 after-market disclosure and the December 7, 2010 statement, Geron stock fell almost 20% in heavy trading, from a December 6, 2010 close of $6.12 to a December 7, ...Geron (GERN) delivered earnings and revenue surprises of -12.50% and 79.29%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?The decision might not be as easy as it seems at first glance.In addition, Geron has granted the underwriters a 30-day option to purchase up to an additional 12,131,444 shares of its common stock, less underwriting discounts and commissions.Pitney Bowes (PBI 6.72%), Geron (GERN 6.11%), and Cummins (CMI 2.55%) were among the worst performers on the day. Below, we'll look more closely at these stocks to tell you why they did so poorly ...

il y a 13 heures ... Geron Corporation (GERN) announced the publication of results from the IMerge Phase 3 trial investigating imetelstat versus placebo in ...

Geron Corporation soared up $0.07 (+2.48%) to $2.89 on typical volume today. It has now increased for the past three days. The increase today helped push this ...

John Scarlett GERN stock SEC Form 4 insiders trading. John has made over 2 trades of the Geron stock since 2013, according to the Form 4 filled with the SEC. Most recently he exercised 1,340,000 units of GERN stock worth $2,010,000 on 8 February 2023.. The largest trade he's ever made was exercising 1,340,000 units of Geron stock …Citigroup Inc. reduced its position in shares of Geron Co. (NASDAQ:GERN – Free Report) by 64.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC).The institutional investor owned 529,339 shares of the biopharmaceutical company’s stock after selling 951,365 shares during the …EVP Chief Operating Officer. 2023-02-09. 150,000. $1.51. $226.50k Buy. 1 of 2. GERN insiders have sold more... subscribe to Premium to read more. Net Insider Buy/Sell (L12M) Ownership. Be the first to know when GERN insiders and whales buy or sell their stock.Apr 20, 2023 · Shares of Geron ( GERN -4.48%), a clinical-stage biotech company, were up more than 30% this week before CEO John A. Scarlett's scheduled appearance at the Needham Virtual Healthcare Conference on ... Penny Stocks To Buy According To Analysts Geron Corp. (GERN) B. Riley: Buy, $5 Target. Shares of Geron have been on the retail trader’s radar following a series of news and industry catalysts. The late-stage biopharmaceutical company specializes in developing treatments for hematologic malignancies.Geron Stock Ownership FAQ. Who owns Geron? Geron (NASDAQ: GERN) is owned by 68.31% institutional shareholders, 1.21% Geron insiders, and 30.48% retail investors. Ra Capital Management LP is the largest individual Geron shareholder, owning 46.20M shares representing 8.51% of the company.

NOTICE OF NEW DEADLINE TO FILE CLAIM OR REQUEST TO BE EXCLUDED FROM THE CLASS . To: All persons who purchased Geron Corporation (“Geron”) common stock during the period from March 19, 2018, to ...Nov 24, 2023 · According to 4 stock analysts, the average 12-month stock price forecast for Geron stock is $4.75, which predicts an increase of 141.12%. The lowest target is $4.00 and the highest is $6.00. On average, analysts rate Geron stock as a strong buy. Stock Price Statistics The stock price has decreased by -16.81% in the last 52 weeks. The beta is 0.82, so Geron's price volatility has been lower than the market average.Geron Corporation Common Stock (GERN) Stock Quotes - Nasdaq offers stock quotes & market activity data for US and global markets.How much institutional selling is happening at Geron? Institutional investors have sold a total of 55,005,341 shares in the last 24 months. This volume of shares sold represents approximately $136.20M in transactions. This page (NASDAQ:GERN) was last updated on 11/21/2023 by MarketBeat.com Staff.

Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of results from the IMerge Phase 3 trial investigating imetelstat ...Geron, based in Foster City, California, was founded by gerontologist Mary C. West and Michael D. West, now CEO of AgeX Therapeutics. [2] [3] They secured initial venture capital investments in the company from Kleiner Perkins Caufield & Byers and Venrock. [4] The company was incorporated in 1990 and began doing business in 1992.

Feb 2, 2023 · GERN - Free Report) closed at $3.34 in the latest trading session, marking a -1.18% move from the prior day. This move lagged the S&P 500's daily gain of 1.47%. Elsewhere, the Dow lost 0.11% ... Geron Corp Stock Forecast, Predictions & Price Target. Add to Watchlist. Overview Forecast. Earnings Dividend Ownership. Analyst price target for GERN. All Analysts Top Analysts. Based on 3 analysts offering 12 month price targets for Geron Corp. Min Forecast. $4.00 +109.42%. Avg Forecast. $4.67 +144.35%.Oct 3, 2023 · Given the large stake in the stock by institutions, Geron's stock price might be vulnerable to their trading decisions ; 51% of the business is held by the top 15 shareholders ; Insiders have been buying lately ; Every investor in Geron Corporation (NASDAQ:GERN) should be aware of the most powerful shareholder groups. We can see that ... Cytokinetics, Geron, and Sangamo are still seeking their first drug approval. Adam Pardee. By Ron Leuty – Senior Reporter, San Francisco Business Times. ... it saw its stock shoot up by a third.Stock analysis for Geron Corp (GERN:NASDAQ GS) including stock price, stock chart, company news, key statistics, fundamentals and company profile.BRITISH & AMERICAN INVESTMENT TRUST PLC FINANCIAL HIGHLIGHTS For the six months ended 30 June 2018 Unaudited 6 months to 30 June …

What is the target price for Geron (GERN) stock? A. The latest price target for Geron ( NASDAQ: GERN) was reported by Goldman Sachs on Tuesday, September 12, 2023. The analyst firm set a price ...

Geron Corporation (NASDAQ:GERN) Q3 2023 Earnings Call Transcript November 2, 2023 Geron Corporation beats earnings expectations. Reported EPS is $-0.08, expectations were $-0.1. Operator: Good morning. My name is Audrey, and I will be your conference operator today. At this time, I would like to welcome everyone to the Geron Corporation Third ...

^ "Geron plans stock offering, Merck buying $18M in shares". 12 September 2005. ^ "Geron Scraps GRN1005, Cuts Jobs". Zacks Investment Research. Retrieved 15 ...Geron Corporation Common Stock (GERN) After-Hours Stock Quotes - Nasdaq offers after-hours quotes and extended trading activity data for US and global markets.Apple Inc. Common Stock. $191.45 +1.76 +0.93%. Geron Corporation Common Stock (GERN) Pre-Market Stock Quotes - Nasdaq offers pre-market quotes and pre-market activity data for US and global markets. This means that the stock's trading pattern over the last month have been neutral. Geron Corp currently has the 131th highest Short-Term Technical score in the Biotechnology industry. The Short-Term Technical score evaluates a stock's trading pattern over the past month and is most useful to short-term stock and option traders.Geron (GERN) Stock Price, News & Info | The Motley Fool Geron (NASDAQ: GERN) $1.97 (1.0%) $0.02 Price as of November 24, 2023, 1:00 p.m. ET Key Data Points Current Price $1.97 Daily Change...Geron GERN has high hopes for drug candidates in its pipeline. It had a successful phase 3 clinical trial with its Imetelstat medication, which would be used to treat lower-risk myelodysplastic syndromes. Geron stock is having an up-and-down start to 2023, rising as high as 40% but then failing to hold on to its gains.Real time Geron (GERN) stock price quote, stock graph, news & analysis. Geron Corporation (Nasdaq: GERN), a late-stage clinical biopharmaceutical company, today announced publication in The Lancet of results from the IMerge Phase 3 …Geron shareholders would also receive BioTime stock-purchase warrants presently valued at approximately $13 million. Geron would retain its cancer therapy business, including Imetelstat and GRN1005, and its cash and short-term liquid investments and Geron shareholders would continue to own 100% of the Geron cancer therapy business …Reported on 11/2/23. Get the latest Geron Corp (GERN) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment...

Asterias has ties to a stock promotion and faces a near-term need to raise significant capital. Asterias' pipeline was abandoned by Geron in 2011 after showing no signs of efficacy in its first ...Geron Corp. GERN (U.S.: Nasdaq) Overview News Geron Corp. No significant news for in the past two years. Key Stock Data Shares Sold Short 44.48 M Change from Last -1.43% Percent of Float...Analysts publish ratings and price targets on most stocks. Benzinga tracks 120 analyst firms so investors can understand if analysts expect a stock to trade higher or lower. Ratings are ...Instagram:https://instagram. how much is a gold.bar worthcat financialcandle graph explanationstocks under dollar5 As of 11:43 a.m. EST, Geron's stock was down by 8.7% after falling by as much as 10.1% earlier in the day. So what. For its 2020 fourth quarter, ending on Dec. 31, Geron reported revenue (from ...Geron has generated ($0.34) earnings per share over the last year ( ($0.34) diluted earnings per share). Earnings for Geron are expected to grow in the coming year, from ($0.35) to ($0.31) per share. Geron has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, March 21st, … after market moverhkdstock Geron Corporation (GERN) announced Tuesday that the U.S. FDA accepted its marketing application for blood cancer therapy imetelstat for standard review. Read more here. day trader strategies GERN - Free Report) closed at $3.34 in the latest trading session, marking a -1.18% move from the prior day. This move lagged the S&P 500's daily gain of 1.47%. Elsewhere, the Dow lost 0.11% ...Geron Corp Stock Forecast, Predictions & Price Target. Add to Watchlist. Overview Forecast. Earnings Dividend Ownership. Analyst price target for GERN. All Analysts Top Analysts. Based on 3 analysts offering 12 month price targets for Geron Corp. Min Forecast. $4.00 +109.42%. Avg Forecast. $4.67 +144.35%.Goldman Sachs analyst Corinne Jenkins maintained a Hold rating on Geron (GERN – Research Report) today.The company’s shares closed yesterday at $3.16. Jenkins covers the Healthcare sector ...